Literature DB >> 31529216

Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Jordi Creus-Muncunill1, Michelle E Ehrlich2.   

Abstract

Huntington's disease (HD) is an autosomal dominant disorder caused by an expansion in the trinucleotide CAG repeat in exon-1 in the huntingtin gene, located on chromosome 4. When the number of trinucleotide CAG exceeds 40 repeats, disease invariably is manifested, characterized by motor, cognitive, and psychiatric symptoms. The huntingtin (Htt) protein and its mutant form (mutant huntingtin, mHtt) are ubiquitously expressed but although multiple brain regions are affected, the most vulnerable brain region is the striatum. Striatal medium-sized spiny neurons (MSNs) preferentially degenerate, followed by the cortical pyramidal neurons located in layers V and VI. Proposed HD pathogenic mechanisms include, but are not restricted to, excitotoxicity, neurotrophic support deficits, collapse of the protein degradation mechanisms, mitochondrial dysfunction, transcriptional alterations, and disorders of myelin. Studies performed in cell type-specific and regionally selective HD mouse models implicate both MSN cell-autonomous properties and cell-cell interactions, particularly corticostriatal but also with non-neuronal cell types. Here, we review the intrinsic properties of MSNs that contribute to their selective vulnerability and in addition, we discuss how astrocytes, microglia, and oligodendrocytes, together with aberrant corticostriatal connectivity, contribute to HD pathophysiology. In addition, mHtt causes cell-autonomous dysfunction in cell types other than MSNs. These findings have implications in terms of therapeutic strategies aimed at preventing neuronal dysfunction and degeneration.

Entities:  

Keywords:  Cell-autonomous; corticostriatal; glia; medium spiny neurons; non-cell-autonomous

Mesh:

Substances:

Year:  2019        PMID: 31529216      PMCID: PMC6985401          DOI: 10.1007/s13311-019-00782-9

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  222 in total

Review 1.  Proteostasis in Huntington's disease: disease mechanisms and therapeutic opportunities.

Authors:  Rachel J Harding; Yu-Feng Tong
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

Review 2.  Huntingtin: here, there, everywhere!

Authors:  Cristovao Marques Sousa; Sandrine Humbert
Journal:  J Huntingtons Dis       Date:  2013

Review 3.  Huntington disease.

Authors:  J P Vonsattel; M DiFiglia
Journal:  J Neuropathol Exp Neurol       Date:  1998-05       Impact factor: 3.685

Review 4.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 5.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

6.  Global cerebral atrophy in early stages of Huntington's disease: quantitative MRI study.

Authors:  Jan Kassubek; G Bernhard Landwehrmeyer; Daniel Ecker; Freimut D Juengling; Rainer Muche; Sabine Schuller; Adolf Weindl; Alexander Peinemann
Journal:  Neuroreport       Date:  2004-02-09       Impact factor: 1.837

7.  Trinucleotide repeat length instability and age of onset in Huntington's disease.

Authors:  M Duyao; C Ambrose; R Myers; A Novelletto; F Persichetti; M Frontali; S Folstein; C Ross; M Franz; M Abbott
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

8.  Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis.

Authors:  H D Rosas; W J Koroshetz; Y I Chen; C Skeuse; M Vangel; M E Cudkowicz; K Caplan; K Marek; L J Seidman; N Makris; B G Jenkins; J M Goldstein
Journal:  Neurology       Date:  2003-05-27       Impact factor: 9.910

Review 9.  Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

Authors:  Shi-Hua Li; Xiao-Jiang Li
Journal:  Trends Genet       Date:  2004-03       Impact factor: 11.639

Review 10.  Ubiquitin-proteasome system involvement in Huntington's disease.

Authors:  Zaira Ortega; Jose J Lucas
Journal:  Front Mol Neurosci       Date:  2014-09-29       Impact factor: 5.639

View more
  13 in total

1.  Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.

Authors:  Carlos Cepeda; Michael S Levine
Journal:  Neuroscientist       Date:  2020-11-16       Impact factor: 7.235

Review 2.  Targeting microglia L-type voltage-dependent calcium channels for the treatment of central nervous system disorders.

Authors:  Sarah C Hopp
Journal:  J Neurosci Res       Date:  2020-01-29       Impact factor: 4.433

Review 3.  Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review.

Authors:  Hannah S Bakels; Raymund A C Roos; Willeke M C van Roon-Mom; Susanne T de Bot
Journal:  Mov Disord       Date:  2021-10-12       Impact factor: 9.698

Review 4.  Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs.

Authors:  Walter H Moos; Douglas V Faller; Ioannis P Glavas; David N Harpp; Iphigenia Kanara; Anastasios N Mavrakis; Julie Pernokas; Mark Pernokas; Carl A Pinkert; Whitney R Powers; Konstantina Sampani; Kosta Steliou; Demetrios G Vavvas; Robert J Zamboni; Krishna Kodukula; Xiaohong Chen
Journal:  Biores Open Access       Date:  2020-03-31

Review 5.  Circuit Mechanisms of Neurodegenerative Diseases: A New Frontier With Miniature Fluorescence Microscopy.

Authors:  Craig T Werner; Christopher J Williams; Mercedes R Fermelia; Da-Ting Lin; Yun Li
Journal:  Front Neurosci       Date:  2019-10-31       Impact factor: 4.677

6.  The Proteasome Activators Blm10/PA200 Enhance the Proteasomal Degradation of N-Terminal Huntingtin.

Authors:  Azzam Aladdin; Yanhua Yao; Ciyu Yang; Günther Kahlert; Marvi Ghani; Nikolett Király; Anita Boratkó; Karen Uray; Gunnar Dittmar; Krisztina Tar
Journal:  Biomolecules       Date:  2020-11-20

Review 7.  Non-Cell-Autonomous Regulation of Optic Nerve Regeneration by Amacrine Cells.

Authors:  Elena G Sergeeva; Paul A Rosenberg; Larry I Benowitz
Journal:  Front Cell Neurosci       Date:  2021-04-16       Impact factor: 5.505

8.  Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease.

Authors:  Mehdi Eshraghi; Pabalu P Karunadharma; Juliana Blin; Neelam Shahani; Emiliano P Ricci; Audrey Michel; Nicolai T Urban; Nicole Galli; Manish Sharma; Uri Nimrod Ramírez-Jarquín; Katie Florescu; Jennifer Hernandez; Srinivasa Subramaniam
Journal:  Nat Commun       Date:  2021-03-05       Impact factor: 14.919

9.  Deficits in coordinated neuronal activity and network topology are striatal hallmarks in Huntington's disease.

Authors:  S Fernández-García; J G Orlandi; G A García-Díaz Barriga; M J Rodríguez; M Masana; J Soriano; J Alberch
Journal:  BMC Biol       Date:  2020-05-28       Impact factor: 7.431

10.  RTP801/REDD1 Is Involved in Neuroinflammation and Modulates Cognitive Dysfunction in Huntington's Disease.

Authors:  Leticia Pérez-Sisqués; Júlia Solana-Balaguer; Genís Campoy-Campos; Núria Martín-Flores; Anna Sancho-Balsells; Marcel Vives-Isern; Ferran Soler-Palazón; Marta Garcia-Forn; Mercè Masana; Jordi Alberch; Esther Pérez-Navarro; Albert Giralt; Cristina Malagelada
Journal:  Biomolecules       Date:  2021-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.